OXYGEN BIOTHERAPEUTICS, INC. 4
4 · OXYGEN BIOTHERAPEUTICS, INC. · Filed Nov 15, 2013
Insider Transaction Report
Form 4
Kelley John P
Chief Executive Officer
Transactions
- Award
Series E Preferred Stock
2013-11-13+8,248→ 8,248 total - Award
Common Stock
2013-11-13+341,711→ 341,711 total
Footnotes (2)
- [F1]The reporting person acquired the securities in connection with the sale of substantially all assets of Phyxius Pharma, Inc. to a wholly owned subsidiary of Oxygen Biotherapeutics, Inc. (the "Transaction").
- [F2]In connection with the Transaction, 1,749 shares of the reporting person?s Series E Preferred Stock are being held in escrow to satisfy indemnification obligations.